Results 1 to 10 of about 26,816 (163)

A Novel Aptamer LL4A Specifically Targets Vemurafenib-Resistant Melanoma through Binding to the CD63 Protein [PDF]

Molecular Therapy: Nucleic Acids, 2019
Melanoma is a highly aggressive tumor with a poor prognosis, and half of all melanoma patients harbor BRAF mutations. A BRAF inhibitor, vemurafenib (PLX4032), has been approved by the US Food and Drug Administration (FDA) and European Medicines Agency ...
Hui Li, Juan Liu, Xiaojuan Xiao, Shuming Sun, Hui Zhang, Yibin Zhang, Weihua Zhou, Bin Zhang, Mridul Roy, Hong Liu, Mao Ye, Zi Wang, Feng Liu-Smith, Jing Liu   +13 more
doaj   +3 more sources

LINC01198 activates Hippo signaling to stimulate IL-1β autocrine for driving vemurafenib resistance by associating with TAOK1/2 in melanoma [PDF]

Cell Death Discovery
Vemurafenib (VEM) is an important targeted drug for treating melanoma harboring BRAF-V600E mutation. Despite its remarkable curative efficacy in early clinical treatment, most patients developed drug resistance within one year. Nevertheless, the critical
Jieyu Liu, Xiaoting Liang, Ke Wang, Chunting Zhang, Can Li, Lei Zhao, Yanjie Kuang, Min Wang, Jun Liu, Liang Zhou, Li Ma   +10 more
doaj   +2 more sources

Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients [PDF]

Journal of Hematology & Oncology, 2017
Background Metastatic melanoma is an aggressive form of skin cancer with a high mortality rate and the fastest growing global incidence rate of all malignancies. The introduction of BRAF/MEK inhibitor combinations has yielded significant increases in PFS
Adil Daud, Japinder Gill, Sheily Kamra, Lei Chen, Amit Ahuja   +4 more
doaj   +4 more sources

Effective vemurafenib monotherapy for refractory Langerhans cell histiocytosis with sustained results post-withdrawal for over two years: a case report [PDF]

Frontiers in Oncology
BackgroundLangerhans cell histiocytosis (LCH) is a rare, inflammatory myeloid neoplasm. Mitogen-activated protein kinase (MAPK) inhibitors, such as vemurafenib, can quickly control active disease in patients resistant to vinblastine and prednisone, but ...
Jiaxin Ren, Jiaxin Ren, Ling Gu, Xue Tang, Xue Tang   +4 more
doaj   +2 more sources

Inter-Relationship Between Melanoma Vemurafenib Tolerance Thresholds and Metabolic Pathway Choice [PDF]

Cells
Melanomas quickly acquire resistance to vemurafenib, an important therapeutic for BRAFV600 mutant melanomas. Although combating vemurafenib resistance (VemR) to counter mitochondrial metabolic shift using mitochondria-targeting therapies has promise, no ...
Pratima Nangia-Makker, Madison Ahrens, Neeraja Purandare, Siddhesh Aras, Jing Li, Katherine Gurdziel, Hyejeong Jang, Seongho Kim, Malathy P Shekhar   +8 more
doaj   +2 more sources

Design, Synthesis, and Bioactivity Assessment of Modified Vemurafenib Analog [PDF]

Pharmaceuticals
Background: Metastatic melanoma is a highly aggressive malignancy with poor prognoses and frequent resistance to conventional chemotherapy. Approximately 40% of melanoma cases carry the BRAFV600E mutation, for which vemurafenib, a selective BRAFV600E ...
Fabiana Sélos Guerra, Rosana Helena Coimbra Nogueira de Freitas, Florina Moldovan, David Rodrigues da Rocha, Renato Sampaio Carvalho, Patricia Dias Fernandes   +5 more
doaj   +2 more sources

Bilirubin Restrains the Anticancer Effect of Vemurafenib on BRAF-Mutant Melanoma Cells Through ERK-MNK1 Signaling

Frontiers in Oncology, 2021
Melanoma, the most threatening cancer in the skin, has been considered to be driven by the carcinogenic RAF-MEK1/2-ERK1/2 signaling pathway. This signaling pathway is usually mainly dysregulated by mutations in BRAF or RAS in skin melanomas.
Yufan Tan, Xiaoyu Zhong, Xiaoyu Zhong, Xizhi Wen, Leyi Yao, Zhenlong Shao, Wenshuang Sun, Jiawen Wu, Guanmei Wen, Daolin Tang, Xiaoshi Zhang, Yuning Liao, Yuning Liao, Jinbao Liu, Jinbao Liu   +14 more
doaj   +1 more source

Mechanisms Underpinning Increased Plasma Creatinine Levels in Patients Receiving Vemurafenib for Advanced Melanoma. [PDF]

PLoS ONE, 2016
Serum creatinine has been reported to increase in patients receiving Vemurafenib, yet neither the prevalence nor the mechanism of this adverse event are known.We aimed to evaluate the frequency and the mechanisms of increases in plasma creatinine level ...
Charlotte Hurabielle, Evangéline Pillebout, Thomas Stehlé, Cécile Pagès, Jennifer Roux, Pierre Schneider, Sylvie Chevret, Cendrine Chaffaut, Anne Boutten, Samia Mourah, Nicole Basset-Seguin, Emmanuelle Vidal-Petiot, Céleste Lebbé, Martin Flamant   +13 more
doaj   +1 more source

Preparation and characterization of vemurafenib microemulsion

Iraqi Journal of Pharmaceutical Sciences, 2023
Human melanoma is the most common and malignant type of skin cancer. Vemurafenib has been used for the treatment of malignant or metastatic melanoma. Oral vemurafenib has serious adverse drug reactions including QTc sigment prolongation of heart ECG ...
Mohammed Jassim Neamah, Entidhar J. Al-Akkam   +1 more
doaj   +1 more source

Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance

Heliyon, 2023
More than one half melanoma patients have BRAF gene mutation. BRAF inhibitor vemurafenib is an effective medication for these patients. However, acquired resistance is generally inevitable, the mechanisms of which are not fully understood.
Jianyu Peng, Zijun Lin, Weichun Chen, Jie Ruan, Fan Deng, Lin Yao, Minla Rao, Xingdong Xiong, Shun Xu, Xiangning Zhang, Xinguang Liu, Xuerong Sun   +11 more
doaj   +1 more source